Global Rivastigmine Oral Market By Type (1.5 mg Capsules, 3 mg Capsules, 4.5 mg Capsules, 6 mg Capsules, 2mg/ml Oral Solution), By Application (Alzheimer’s disease, Parkinson’s), Forecast (2022-2028)

The global rivastigmine oral market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The global rivastigmine oral market is driven primarily by the growing geriatric population which is more prone to chronic diseases such as alzheimer’s disease. As a result, there is an increase in the use of prescription drugs for older adults globally. Prescription drugs have evolved over time because of the invention of new active substances and changes in their manufacturing that make them easier to use with fewer side effects or side effects. Moreover, according to FDA, the high growth rate in this category may be due to an increase in the number of adults and an increase in cases of dementia worldwide, accompanied by a growing awareness of the various treatment options for alzheimer’s and Parkinson’s disease now available compared to a few years ago.

 

For instance, in 2020, the US healthcare sector accounts for about 16.0% of the country’s GDP, and the costs generated by rivastigmine oral and other dementia are estimated to exceed $300 Billion. In addition, the increase in the number of health facilities has ensured easy access to treatment options, thus serving as a catalyst for the growth of the rivastigmine oral market. Therefore, currently, there are more than 6,100 hospitals operating in the country and due to recent developments in the healthcare industry, the increase ofpatients with rivastigmine oraldisease has increased in the last few years in the US. These factors are one of the major indicators of growth following the significant growth of the rivastigmine oral treatment its grownthe rivastigmine oral market in North America.

 

AAllergan, Eisai Co., Ltd., Novartis AG, DaiichiSankyo., Ltd., Merz Pharma, Pfizer Inc., Johnson & Johnson Services, Inc., among others are some key players that are making a significant contribution to the growth of the rivastigmine oral market by the adoption of several growth strategies such as mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches. For instance, in June 2021, the US FDA has approved the first treatment of rivastigmine oralthat is addressing the underlying pathology and the anti-amyloid antibody aducanumab of Biogen and Eisai, now called Aduhelm, this removes amyloid plaque from the brain. Approval of such medications is anticipated to drive the growth of the global rivastigmine oral market.

 

Market Coverage

 

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape-Allergan, Eisai Co., Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd.,DaiichiSankyoCo., Ltd., Merz Pharma, Pfizer Inc.,  and Johnson & Johnson Services, Inc., among others.

 

Key questions addressed by the report

 

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Rivastigmine Oral Market Report by Segment

 

By Application

• Alzheimer Disease
• Parkinson’s Disease

By Type

• 5 mg Capsules,
• 3 mg Capsules,
• 5 mg Capsules,
• 6 mg Capsules,
• 2mg/ml Oral Solution

By Distribution Channel

• Hospital Pharmacies,
• Retail Pharmacies
• Online Pharmacies

 

Global Rivastigmine Oral Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa